NNVC
HEALTHCARENanoViricides Inc
$1.46+0.00 (+0.00%)PRE
Live · AMEX · May 9, Close
AI Insight
What's Moving NNVC Today?
No stock-specific AI insight has been generated for NNVC yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.85$2.23
$1.46
Fundamentals
Market Cap$32M
P/E Ratio—
EPS$-0.49
Dividend Yield—
Dividend / Share—
ROE-0.8%
Profit Margin—
Debt / Equity—
Trading
Volume211K
Avg Volume (10D)—
Shares Outstanding21.6M
NNVC News
20 articles- NanoViricides to Participate at D. Boral Capital Global Conference in NYCYahoo Finance·May 7, 2026
- NanoViricides (NNVC) Secures FDA Orphan Drug Status for NV-387 Measles TreatmentYahoo Finance·May 7, 2026
- NanoViricides, Inc. Announces Participation in the D. Boral Capital Global ConferenceYahoo Finance·May 6, 2026
- NanoViricides’ Measles Treatment Granted Orphan Drug Designation by FDAYahoo Finance·May 6, 2026
- NanoViricides antiviral drug NV-387 wins FDA Orphan Drug Designation for measles treatmentProactive Investors·May 4, 2026
- NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDAYahoo Finance·May 4, 2026
- NanoViricides says NV-387 could address measles outbreaks as cases rise globallyProactive Investors·Apr 21, 2026
- Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricidesYahoo Finance·Apr 21, 2026
- NanoViricides seeks FDA’s rare pediatric disease designation for antiviral candidate NV-387 - ICYMIProactive Investors·Apr 11, 2026
- NanoViricides files for Rare Pediatric Disease Designation for Measles DrugYahoo Finance·Apr 9, 2026
- NanoViricides seeks rare pediatric disease status for measles drug NV-387Proactive Investors·Apr 7, 2026
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricidesYahoo Finance·Apr 7, 2026
- NanoViricides to begin Phase II trial of MPox treatment in CongoProactive Investors·Apr 1, 2026
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricidesYahoo Finance·Apr 1, 2026
- NanoViricides completes manufacturing of NV-387 oral drug ahead of Phase II mpox trialProactive Investors·Mar 11, 2026
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is CompleteYahoo Finance·Mar 11, 2026
- NanoViricides CEO discusses progress of broad-spectrum antiviral candidate NV-387 - ICYMIProactive Investors·Feb 21, 2026
- NanoViricides advances broad-spectrum antiviral NV-387 towards Phase II MPox studyProactive Investors·Feb 19, 2026
- NanoViricides advances toward fully funded Phase II MPox trial in DRCYahoo Finance·Feb 18, 2026
- NanoViricides: Fiscal Q2 Earnings SnapshotYahoo Finance·Feb 17, 2026
All 20 articles loaded
Price Data
Open$1.33
Previous Close$1.46
Day High$1.51
Day Low$1.30
52 Week High$2.23
52 Week Low$0.85
52-Week Range
$0.85$2.23
$1.46
Fundamentals
Market Cap$32M
P/E Ratio—
EPS$-0.49
Dividend Yield—
Dividend / Share—
ROE-0.8%
Profit Margin—
Debt / Equity—
Trading
Volume211K
Avg Volume (10D)—
Shares Outstanding21.6M
About NanoViricides Inc
NanoViricides, Inc., a nanobiopharmaceutical company, discovers, develops and markets drugs for the treatment of viral infections. The company is headquartered in Shelton, Connecticut.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeAMEX
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—